Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study
Diagnostics · 18.11.2026 · 16 (22) · 3845
DOI: 10.3390/diagnostics16223845 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 18.11.2026. Verfasst von Lena Weindl und 7 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Efanesoctocog alfa (EFA) is an extended half-life factor VIII (FVIII) concentrate. Although FVIII assay variability in EFA monitoring is established, data on the comparability of activated partial thromboplastin time (aPTT) reagents remain limited. This study compared Actin FSL and Pathromtin SL in post-infusion EFA samples, assessed lot-to-lot variability, and evaluated aPTT performance in detecting reduced FVIII activity.
Methods
This retrospective, single-center study analyzed 106 paired samples from 53 patients receiving once-weekly EFA at trough level, peak level (1 h post-infusion), or follow-up (median 4.0 days). FVIII activity was measured using an Actin FSL-based one-stage clotting assay with FVIII-deficient plasma. aPTT was determined using Actin FSL and Pathromtin SL on Sysmex coagulation analyzers. Method comparison included Passing–Bablok regression and modified Bland–Altman analysis.
Results
Pathromtin SL produced longer clotting times (mean bias: 5.2 s, mean relative difference: 13.1%). Both aPTT reagents showed a strong correlation in post-infusion EFA samples (Pearson’s r = 0.878). No significant differences in regression slopes were observed across reagent lot combinations; maximum relative inter-lot difference was 6.5%. Using assay-specific cut-offs, both aPTT assays showed 100% sensitivity for detecting FVIII activity < 30% in this cohort. Nevertheless, prolonged aPTT values also occurred at FVIII activity ≥ 30%, indicating limited specificity.
Conclusions
Both Actin FSL and Pathromtin SL aPTT assays identified all samples with Actin FSL-based FVIII activity < 30%. However, significantly longer clotting times with Pathromtin SL necessitate assay-specific interpretation in clinical practice. Findings should be interpreted considering the limited sample size, retrospective single-center design and potential methodological dependency.
Zitieren
APA
Weindl, L., Olivieri, M., Northoff, B. H., Spannagl, M., Patzke, J., Weigand, M., Teupser, D., & Bruegel, M. (2026). Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study. Diagnostics, 16(22), 3845. https://doi.org/10.3390/diagnostics16223845
Vancouver
Weindl L, Olivieri M, Northoff BH, Spannagl M, Patzke J, Weigand M, et al. Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study. Diagnostics. 2026;16(22):3845. doi:10.3390/diagnostics16223845
BibTeX
@article{Weindl2026,
author = {Weindl, Lena and Olivieri, Martin and Northoff, Bernd H. and Spannagl, Michael and Patzke, Juergen and Weigand, Michael and Teupser, Daniel and Bruegel, Mathias},
title = {Comparison of Actin FSL and Pathromtin SL aPTT Reagents in Patients Receiving Efanesoctocog Alfa: A Retrospective Laboratory Study},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {22},
pages = {3845},
doi = {10.3390/diagnostics16223845}
}
EUVIMED